| Serial Number | 88408998 |
| Word Mark | VYMIRIO |
| Filing Date | Tuesday, April 30, 2019 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, December 5, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 8, 2020 |
| Goods and Services | pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors |
| Goods and Services | research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 16, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 16, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Mirati Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Mirati Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Event Date | Event Description |
| Monday, December 5, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, December 5, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Friday, April 29, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, April 27, 2022 | SOU EXTENSION 3 GRANTED |
| Wednesday, April 27, 2022 | SOU EXTENSION 3 FILED |
| Wednesday, April 27, 2022 | TEAS EXTENSION RECEIVED |
| Friday, October 8, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, October 6, 2021 | SOU EXTENSION 2 GRANTED |
| Wednesday, October 6, 2021 | SOU EXTENSION 2 FILED |
| Wednesday, October 6, 2021 | TEAS EXTENSION RECEIVED |
| Thursday, April 29, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, April 27, 2021 | SOU EXTENSION 1 GRANTED |
| Tuesday, April 27, 2021 | SOU EXTENSION 1 FILED |
| Tuesday, April 27, 2021 | TEAS EXTENSION RECEIVED |
| Tuesday, November 3, 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, September 8, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 8, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 19, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, August 3, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, July 24, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, July 23, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 23, 2020 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, February 4, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, February 4, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Saturday, January 25, 2020 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Saturday, January 25, 2020 | FINAL REFUSAL E-MAILED |
| Saturday, January 25, 2020 | FINAL REFUSAL WRITTEN |
| Tuesday, January 14, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 14, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 14, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, July 15, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, July 15, 2019 | NON-FINAL ACTION E-MAILED |
| Monday, July 15, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, July 12, 2019 | ASSIGNED TO EXAMINER |
| Thursday, May 16, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, May 3, 2019 | NEW APPLICATION ENTERED |